Literature DB >> 15328901

Atypical antipsychotic induced weight gain: pathophysiology and management.

Jambur Ananth1, Ravi Venkatesh, Karl Burgoyne, Rangaesh Gadasalli, Robert Binford, Sarath Gunatilake.   

Abstract

There is compelling evidence that patients with schizophrenia are prone to gain weight. In addition, atypical antipsychotic (AAP) drugs also induce weight gain. All antipsychotic drugs produce weight gain but the potential varies. Many studies overwhelmingly confirm that AAP drugs produce substantially more weight gain in comparison to conventional antipsychotic drugs. Clozapine and olanzapine have the most weight inducing potential. Even ziprasidone, which is considered to be weight neutral, and aripiprazole a dopamine modulator produce weight gain in some. The pathophysiology of weight gain is complicated. Many neurohormones, neuropeptides, gut hormones, as well as adipose tissue and hair root derived hormones interact with environmental factors to produce weight gain. Management of weight gain is a difficult problem. Basic to treatment is an understanding of the etiology. Drug induced obesity provides a unique opportunity to psychiatrists to understand this clinically important problem. In the absence of this knowledge, prevention is the best hope. Education, diet control and simple behavioral measures may prevent excessive weight gain. In those with weight gain, treatment can be attempted with pharmacotherapy with careful monitoring of the side effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15328901     DOI: 10.1080/10401230490453293

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  15 in total

Review 1.  Are atypical antipsychotics safer than typical antipsychotics for treating behavioral and psychological symptoms of dementia?

Authors:  A Gurevich; V Guller; Y N Berner; S Tal
Journal:  J Nutr Health Aging       Date:  2012       Impact factor: 4.075

Review 2.  [Antipsychotic drug-induced changes in metabolism].

Authors:  Julia Engl; Alexander Tschoner; Markus Laimer; Maria Rettenbacher; W Wolfgang Fleischhacker; Josef R Patsch; Christoph Ebenbichler
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

Review 3.  Interventions to reduce weight gain in schizophrenia.

Authors:  G Faulkner; T Cohn; G Remington
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 4.  Atypical antipsychotics and diabetic ketoacidosis: a review.

Authors:  Melanie D Guenette; Margaret Hahn; Tony A Cohn; Celine Teo; Gary J Remington
Journal:  Psychopharmacology (Berl)       Date:  2013-01-24       Impact factor: 4.530

5.  Effect of a motivational group intervention upon exercise self efficacy and outcome expectations for exercise in Schizophrenia Spectrum Disorders (SSDs).

Authors:  Lora Humphrey Beebe; Kathlene Smith; Renee Burk; Olivera Dessieux; Dawn Velligan; Abbas Tavakoli; Clif Tennison
Journal:  J Am Psychiatr Nurses Assoc       Date:  2010-04       Impact factor: 2.385

6.  Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia.

Authors:  Christina P C Borba; Xiaoduo Fan; Paul M Copeland; Alexander Paiva; Oliver Freudenreich; David C Henderson
Journal:  J Clin Psychopharmacol       Date:  2011-10       Impact factor: 3.153

7.  Feasibility of the Walk, Address, Learn and Cue (WALC) Intervention for schizophrenia spectrum disorders.

Authors:  Lora Humphrey Beebe; Kathlene Smith
Journal:  Arch Psychiatr Nurs       Date:  2009-08-06       Impact factor: 2.218

8.  Motivating Persons with Schizophrenia Spectrum Disorders to Exercise: Rationale and Design.

Authors:  Lora Humphrey Beebe; R Burk; K McIntyre; K Smith; D Velligan; B Resnick; A Tavakoli; C Tennison; O Dessieux
Journal:  Clin Schizophr Relat Psychoses       Date:  2009-07-01

9.  Effect of a motivational intervention on exercise behavior in persons with schizophrenia spectrum disorders.

Authors:  Lora Humphrey Beebe; Kathy Smith; Renee Burk; Kelly McIntyre; Olivera Dessieux; Abbas Tavakoli; Clif Tennison; Dawn Velligan
Journal:  Community Ment Health J       Date:  2010-11-27

Review 10.  Animal models of eating disorders.

Authors:  S F Kim
Journal:  Neuroscience       Date:  2012-03-21       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.